A Meta-analysis to Assess the FDA DAVP's TLOVR Algorithm in HIV Submissions

被引:54
作者
Smith, Fraser [1 ]
Hammerstrom, Thomas [1 ]
Soon, Greg [1 ]
Zhou, Susan [1 ]
Chen, Baibai [1 ]
Mai, Yabing [1 ]
Struble, Kimberly [2 ]
Huque, Mohammad [1 ]
机构
[1] FDA CDER, Off Translat Sci, Off Biostat, Div Biometr 4, Silver Spring, MD 20993 USA
[2] FDA CDER, Off New Drugs, Off Antimicrobial Prod, Div Antiviral Prod, Silver Spring, MD 20993 USA
来源
DRUG INFORMATION JOURNAL | 2011年 / 45卷 / 03期
关键词
TLOVR algorithm; Snapshot approach; HIV; Meta-analysis; RNA; AIDS;
D O I
10.1177/009286151104500309
中图分类号
R19 [保健组织与事业(卫生事业管理)];
学科分类号
摘要
The first meta-analysis of pivotal HIV study results utilizing data from 1 8 clinical trials involving seven NDAs with 8,046 patients of multiple NDA submissions for the treatment of HIV infection was used to determine if we can use a simplified version of the TLOVR algorithm for accelerated approval at week 24 and possibly for traditional approval at week 48. Standardized data sets for HIV RNA viral load, demography, CD4 counts, and discontinuation were created. These raw data sets used CDISC study data tabulation model naming conventions for most of the variables. Results obtained using the TLOVR algorithm, which utilized data from every visit to consider the pattern of HIV responses, were compared to a less complicated snapshot approach that only utilized HIV RNA data at the visit of interest. Given the similarity in results between the TLOVR and snapshot approaches, it appears that correcting for intermittent spikes in HIV RNA levels with the TLOVR algorithm does not have much regulatory impact.
引用
收藏
页码:291 / 300
页数:10
相关论文
共 9 条
[1]  
Chuang-Stein C, 1998, DRUG INF J, V32, P439, DOI 10.1177/009286159803200215
[2]   Abacavir versus zidovudine combined with lamivudine and efavirenz, for the treatment of antiretroviral-naive HIV-infected adults [J].
DeJesus, E ;
Herrera, G ;
Teofilo, E ;
Gerstoft, J ;
Buendia, CB ;
Brand, JD ;
Brothers, CH ;
Hernandez, J ;
Castillo, SA ;
Bonny, T ;
Lanier, ER ;
Scott, TR .
CLINICAL INFECTIOUS DISEASES, 2004, 39 (07) :1038-1046
[3]  
*DIV ANT DRUG PROD, GUID IND ANT DRUGS U
[4]   The KLEAN study of fosamprenavir-ritonavir versus lopinavir-ritonavir, each in combination with abacovir-lamivudine, for initial treatment of HIV infection over 48 weeks: a randomised non-inferiority trial (vol 368, pg 476, 2006) [J].
Eron, Joseph, Jr. ;
Yeni, Patrick ;
Gathe, Joseph .
LANCET, 2006, 368 (9543) :1238-1238
[5]  
Hill AM, 1998, ANTIVIR THER, V3, P139
[6]   Use of changes in plasma levels of human immunodeficiency virus type 1 RNA to assess the clinical benefit of antiretroviral therapy [J].
Marschner, IC ;
Collier, AC ;
Coombs, RW ;
D'Aquila, RT ;
DeGruttola, V ;
Fischl, MA ;
Hammer, SM ;
Hughes, MD ;
Johnson, VA ;
Katzenstein, DA ;
Richman, DD ;
Smeaton, LM ;
Spector, SA ;
Saag, MS .
JOURNAL OF INFECTIOUS DISEASES, 1998, 177 (01) :40-47
[7]   The use of plasma HIV RNA as a study endpoint in efficacy trials of antiretroviral drugs [J].
Murray, JS ;
Elashoff, MR ;
Iacono-Connors, LC ;
Cvetkovich, TA ;
Struble, KA .
AIDS, 1999, 13 (07) :797-804
[8]  
*SAS I INC, 2004, SAS STAT 9 1 US GUID, V3
[9]  
*SAS I INC, 2004, SAS STAT 9 1 US GUID, V2